This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UK panel sides with Optis, orders Apple to pay $502 million plus interest

By Melissa Ritti ( May 2, 2025, 16:21 GMT | Insight) -- In a divided ruling, the UK Court of Appeal yesterday set fair, reasonable and nondiscriminatory terms for a license to Optis standard essential patents of $0.15 per device, leaving Apple with a $502 million tab for infringement. The award, which could balloon to more than $700 million with interest, is a blow to the software giant, who is simultaneously seeking review of a comparable jury verdict in the US — where it was also deemed an infringer. According to the UK panel, in awarding Optis far less, the UK High Court overlooked Apple’s hold-out.UK High Court Judge Marcus Smith employed an erroneous methodology when declaring fair, reasonable and nondiscriminatory, or Frand, license terms for Optis standard essential patents because he failed to give proper weight to hold-out behavior by Apple, the UK Court of Appeal has ruled....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections